Immunic, Inc.

Stocks

IMUX

US4525EP2001

Real-time Estimate Cboe BZX 10:20:24 13/11/2026 pm IST			5-day change	1st Jan Change
7.760 ^USD	-0.39%		-0.39%	+44.65%

06/11	Immunic, Inc. - Special Call
23/10	Cantor Fitzgerald Initiates Coverage on Immunic With Overweight Rating	MT

Transcript : Immunic, Inc. - Special Call

Published on 11/06/2026 at 01:35 am IST - Modified on 11/10/2026 at 06:35 am IST

S&P Capital IQ

Presenter Speech
Jessica Breu (Executives)

Hello, and welcome to Immunic's Virtual R&D Day focusing on our Progressive MS development program with our investigational asset, Vidofludimus Calcium. I

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Immunic, Inc.

06/11	Immunic, Inc. - Special Call
23/10	Cantor Fitzgerald Initiates Coverage on Immunic With Overweight Rating	MT
21/10	Immunic, Inc. Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations At Mstoronto2026	CI
20/10	Immunic, Inc. Announces Appointment of Jaa Roberson as Chief People Officer, Effective October 19, 2026	CI
07/10	Immunic, Inc. Presents New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium At Mstoronto2026	CI
12/09	Immunic, Inc. Announces Resignation of Duane Nash as Member of the Board of Directors	CI
10/09	Immunic, Inc. - Special Call
01/09	Roth Capital Partners Adjusts Price Target on Immunic to $29 From $19, Maintains Buy Rating	MT
01/09	Immunic, Inc. Announces Appointment of Chitrang Davé to Chief Data and Digital Officer, Effective September 1, 2026	CI
17/08	Wedbush Initiates Immunic at Outperform With $45 Price Target	MT
11/08	Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
11/08	Immunic, Inc. Announces Appointment of Elena Ridloff to Board of Directors, Effective August 6, 2026	CI
07/07	Immunic, Inc. Announces Board and Committee Changes	CI
29/06	Immunic, Inc.(NasdaqCM:IMUX) added to Russell Microcap Value Benchmark Index	CI
29/06	Immunic, Inc.(NasdaqCM:IMUX) added to Russell 3000E Value Benchmark	CI

Chart Immunic, Inc.

Duration

Period

IMUX: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - Immunic, Inc.

More financial data

Ratings

More Ratings

EPS Estimates

Evolution of Analysts' Estimates - EPS - Immunic, Inc.

Revisions to estimates